Targeted Biomolecule for Cognitive Disorders Treatment, API

COOPERATION OPTIONS

LICENSE

FROM 100 MILLION RUR

RESEARCH PARTNERSHIP

FROM 28 MILLION RUR

more detail

ABOUT THE PROJECT

TARGETED BIOMOLECULE FOR COGNITIVE DISORDERS TREATMENT, API

NEW THERAPY FOR NEURODEGENERATIVE DISEASES

By transferring the natural functions of the human Lynx1 protein into small peptide molecules with high stability and effective pharmacokinetics, an increase in neuronal synaptic plasticity is achieved. The first phase of preclinical studies has been completed, and cognitive abilities have been evaluated in behavioral tests in mouse models. In the case of Alzheimer's disease model, it is shown that administration of the drug for 2-3 weeks causes a significant reduction of anxiety and improvement of cognitive abilities (motor memory, olfactory memory). Methods of electrophysiology showed an increase in synaptic plasticity under the action of the drug on experiencing hippocampal slices. 

STAGE OF DEVELOPMENT

TARGETED BIOMOLECULE FOR COGNITIVE DISORDERS TREATMENT, API

COOPERATION OPTIONS

LICENSE

FROM 100 MILLION RUR

RESEARCH PARTNERSHIP

FROM 28 MILLION RUR

more detail

ABOUT THE PROJECT

TARGETED BIOMOLECULE FOR COGNITIVE DISORDERS TREATMENT, API

NEW THERAPY FOR NEURODEGENERATIVE DISEASES

By transferring the natural functions of the human Lynx1 protein into small peptide molecules with high stability and effective pharmacokinetics, an increase in neuronal synaptic plasticity is achieved. The first phase of preclinical studies has been completed, and cognitive abilities have been evaluated in behavioral tests in mouse models. In the case of Alzheimer's disease model, it is shown that administration of the drug for 2-3 weeks causes a significant reduction of anxiety and improvement of cognitive abilities (motor memory, olfactory memory). Methods of electrophysiology showed an increase in synaptic plasticity under the action of the drug on experiencing hippocampal slices. 

STAGE OF DEVELOPMENT

STAGE OF DEVELOPMENT
& RESULTS OF INTELLECTUAL ACTIVITY STATUS


APPLICATION

Therapy and prophylaxis of cognitive disorders associated with cholinergic system dysfunction.

Application form – intranasal.

BENEFITS

Lack of toxicity and immunogenicity

ABILITY TO PENETRATE THE BLOOD-BRAIN BARRIER DURING INTRANASAL ADMINISTRATION
REVERSIBLE BINDING TO THE TARGET RECEPTOR, WHICH EXCLUDES ACCUMULATION OF THE DRUG IN THE BODY
HIGH STABILITY IN AQUEOUS SOLUTION

COOPERATION OPTIONS

Options for project implementation include Intellectual Property license agreement and/or further product development together with investor.
license agreement 

Conclusion of agreements on disposal of exclusive intellectual property rights (license agreements). 

Approximate investment amount: 

• Granting the right to use results of intellectual activity - starting at RUB 100 million RUR

• Royalty 5%

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to bring research to the market launching stage and to organize product manufacturing and sales.

Approximate investment amount: 

Starting at 470 million RUR 

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to reach the further research stage(s) and to sale of the scientific product in the form of sublicensing.

Approximate investment amount:

• Preclinical studies
Starting at 30 million RUR

• Clinical trials, phase 1
Starting at 50 million RUR

• Clinical trials, phase 2
Starting at 150 million RUR

• Clinical trials, phase 3
Starting at 200 million RUR

investment partnership agreements

Conclusion of investment partnership agreements for further research stages on the investor basis with the participation of IBCh RAS.

The aim: to obtain a scientific product or "ready to market" product.

Approximate investment amount: 

• Preclinical studies
Starting at 30 million RUR

• Clinical trials, phase 1
Starting at 50 million RUR

• Clinical trials, phase 2
Starting at 150 million RUR

• Clinical trials, phase 3
Starting at 200 million RUR

• Start manufacturing
Starting at 20 million RUR

• Promotion activities
Starting at 50 million RUR

DEVELOPERS

The Shemyakin & Ovchinnikov Institute of bioorganic chemistry (IBCh) of the Russian Academy of Sciences is one of the largest Russian scientific organizations. The Institute is a leader in fundamental and innovative researches on the fields of molecular, structural and cell biology, bioorganic chemistry, biophysics, bioengineering, cell technologies, “in vivo” molecular based bioimaging, genome editing, bioinformatics etc. This multidisciplinary structure allows large-scale research at the interface of sciences, where the most interesting scientific discoveries are born today.

The hallmark of the IBCh RAS is the concentration of efforts and resources on solving the most urgent and complicated problems on the field of life sciences. Talented young people and leading specialists, including Russian and foreign science leaders, Nobel Prize laureates and members of the international advisory council of the Institute are involved in.

Project Team

PROFESSOR of RAS, Dr of Sc. in Physics and Mathematics

Zakhar Shenkarev

Head of the Laboratory for Bioengineering of Antitumor Drugs and Artificial Neuromodulators, IBCh RAS
Dr. of Sc. in Biology

Ekaterina Lyukmanova

Head of the Laboratory for Bioengineering of Neuromodulators and Neuroreceptors, IBCh RAS


PUBLICATIONS

A drug to restore memory for people with Alzheimer's disease is being developed in Russia

Nicotine by the receptor: protein drops will help with Alzheimer's disease

2020/ Water-soluble variant of human Lynx1 positively modulates synaptic plasticity and ameliorates cognitive impairment associated with α7-nAChR dysfunction.

8. Z.O. Shenkarev, M.A. Shulepko, M.L. Bychkov, D.S. Kulbatskii1, O.V. Shlepova, N.A. Vasilyeva, A.A. Andreev-Andrievsky, A.S. Popova, E.A. Lagereva, E.V. Loktyushov, S.G. Koshelev, M.S. Thomsen, D.A. Dolgikh, S.A. Kozlov, P.M. Balaban, M.P. Kirpichnikov, E.N. Lyukmanova.

Journal of neurochemistry. Volume155, Issue1. Pages 45-61

Lynx1 prevents long-term potentiation blockade and reduction of neuromodulator expression caused by Aβ1-42 and JNK activation

Bychkov ML, Vasilyeva NA, Shulepko MA, Balaban PM, Kirpichnikov MP, Lyukmanova EN.

2018/ Acta Naturae. 2018;3(38):57-61. (рус.61-66)

Three-Finger Proteins from the Ly6/uPAR Family: Functional Diversity within One Structural Motif

Vasilyeva NA, Loktyushov EV, Bychkov ML, Shenkarev ZO, Lyukmanova EN. 2017/

Biochemistry (Mosc). 2017 82(13):1702-1715. doi: 10.1134/S0006297917130090. Review.

Lynx1 and Aβ1–42 bind competitively to multiple nicotinic acetylcholine receptor subtypes

Morten S. Thomsen, Maria Arvaniti, Majbrit M. Jensen, Mikhail A. Shulepko, Dmitry A. Dolgikh, Lars H. Pinborg, Wolfgang Härtig, Ekaterina N. Lyukmanova, Jens D. Mikkelsen.

2016/ Neurobiology of Aging, Volume 46, 2016, Pages 13-21

Expression of the Ly-6 family proteins Lynx1 and Ly6H in the rat brain is compartmentalized, cell-type specific, and developmentally regulated

Thomsen MS, Cinar B, Jensen MM, Lyukmanova EN, Shulepko MA, Tsetlin V, Klein AB, Mikkelsen JD.

(2014) Brain Struct Funct. 219(6):1923-1934.

Ws-LYNX1 Residues Important for Interaction with Muscle-Type and/or Neuronal Nicotinic Receptors

13. Lyukmanova EN, Shulepko MA, Buldakova SL, Kasheverov IE, Shenkarev ZO, Reshetnikov RV, Filkin SY, Kudryavtsev DS, Ojomoko LO, Kryukova EV, Dolgikh DA, Kirpichnikov MP, Bregestovski PD, Tsetlin VI.

(2013) J Biol Chem. 288(22):15888-15899.

Бактериальная продукция водорастворимого домена lynx1, - эндогенного нейромодулятора никотиновых рецепторов человека

М.А. Шулепко, Е.Н. Люкманова, И.Е. Кашеверов, Д.А. Долгих, В.И. Цетлин, М.П. Кирпичников.

Биоорг. хим. (2011), 37(5): 609-615. (543-549)

NMR structure and action on nicotinic acetylcholine receptors of water-soluble domain of human lynx1

E.N. Lyukmanova, Z.O. Shenkarev, M.A. Shulepko, K.S. Mineev, D. D’Hoedt, I.E. Kasheverov, S. Filkin, H. Janickova, V. Dolezal, D.A. Dolgikh, A.S. Arseniev, D. Bertrand, V.I. Tsetlin, M.P. Kirpichnikov.

J.Biol.Chem.(2011), 286: 10618-10627.

CONTACT us

get in touch

On cooperation issues please contact the head of NTI Center project department
Sergey Semenov
E-mail consortium@cnti-ibch.ru
address 16/10, Miklukho-Maklaya St, Moscow, Russian Federation, 117997
All products and services of NTI Center IBHh RAS
view more
Report abuse